Showing 1 - 10 of 7,562
Objectives Policy makers pay more and more attention to the orphan drug market. Pharmaceutical companies are suspected to take advantage of the legislation. Moreover, granted an orphan designation (OD) could be associated with higher prices. The aim of this work is to assess the impact of the...
Persistent link: https://www.econbiz.de/10011074155
Background To reach the French market, a new drug requires a marketing authorization (MA) and price and reimbursement agreements. These hurdles could delay access to new and promising drugs. Since 1992, French law authorizes the use of unlicensed drugs on an exceptional and temporary basis...
Persistent link: https://www.econbiz.de/10010707774
Background Biosimilars are copies of biological reference medicines. Unlike generics (copies of chemical molecules), biologics are complex, expensive and complicated to produce. The knowledge of the factors affecting the competition following patent expiry for biologics remains limited....
Persistent link: https://www.econbiz.de/10011072825
Background Patent expiries on leading biologics are creating new momentum in the market for biosimilars (copies of off-patent biologics), paving the way for their development. However, little is known about the factors influencing the competition between biosimilars and their reference products...
Persistent link: https://www.econbiz.de/10011228183
Persistent link: https://www.econbiz.de/10010706533
BACKGROUND: In 2005, the French Government implemented a new way of financing high-cost drugs for hospitals in order to promote innovation. Such drugs are gathered on a positive list, established by the Ministry of Health, with a reimbursement price cap. Hospitals still negotiate with...
Persistent link: https://www.econbiz.de/10010706947
Price regulation and competition patterns in the ethical drug industry in france This article gives the results of an econometric modelization of the ethical drugs price and quantity determination institutionnal process for France. From price and promotion elasticities, it is shown that...
Persistent link: https://www.econbiz.de/10011096648
Le texte ci-dessous entend contribuer à enrichir le débat sur une des principales innovations qui aient été proposées ces dernières années pour le système de santé. Ce débat doit porter sur la pertinence du constat préalable, sur la logique du projet des Réseaux de Soins Coordonnés...
Persistent link: https://www.econbiz.de/10011096667
Persistent link: https://www.econbiz.de/10011105184
Persistent link: https://www.econbiz.de/10011105185